Source - SMW
C4X Discovery has entered into a multi-target, risk-sharing alliance with Evotec AG, a leading drug discovery alliance and development partnership company. 

The new agreement builds on the strategic collaboration between the two companies announced in January 2015 and will see C4XD and Evotec work together to develop new small molecule drugs across a range of targets, therapeutic areas and stages of development, with the initial programmes targeted towards the treatment of cancer and autoimmune diseases.